Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities:
Net loss	$ (50,785)	$ (45,719)	$ (62,134)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Amortization of deferred revenue	0	0	(12,400)
Depreciation and amortization	31,869	25,352	22,096
Stock-based compensation	12,084	11,809	12,423
Change in fair value of common stock warrants issued to non-employees	0	0	356
Accretion of debt discount, recorded to interest expense on 2018 Convertible Notes (Note 15)	5,250	4,818	43
Amortization of deferred financing costs, recorded to interest expense on 2018 Convertible Notes (Note 15)	662	599	101
Bad debt (recovery) expense	0	(85)	127
Non-cash foreign currency exchange loss (income)	(157)	6,033	1,222
Impairment of intangible assets (Note 3(g))	7,160	0	1,023
Change in fair value of contingent consideration related to Talon and EVOMELA acquisitions (Note 9)	(676)	(987)	(2,871)
Change in fair value of Allos deferred development costs and deferred payment contingency (Note 16)	0	0	(2,869)
Research and development expense recognized for BELEODAQ in-license milestone achievement (Note 17(b)(x))	0	7,790	0
Changes in operating assets and liabilities:
Accounts receivable, net	40,245	(21,671)	42,559
Other receivables	(7,017)	2,070	0
Inventories	1,863	4,253	1,570
Prepaid expenses and current portion of other assets	(446)	(718)	(359)
Deferred tax assets	0	1,724	33,252
Other assets	(1,731)	(13,161)	(8,989)
Accounts payable and other accrued obligations	(28,298)	5,304	(23,897)
Accrued payroll and benefits	(233)	1,594	425
Drug development liability	(1,100)	(1,957)	(5,917)
Deferred revenue	(3,511)	9,803	0
Deferred tax liability	210	(602)	0
Other long-term liabilities	1,355	124	2,153
Net cash provided by (used in) operating activities	6,744	(3,627)	(2,086)
Cash Flows From Investing Activities:
Purchases of property and equipment	(223)	(934)	(161)
Proceeds from sale of available-for-sale securities	3,061	4,093	0
Net cash provided by (used in) investing activities	2,838	(21,841)	(14,330)
Cash Flows From Financing Activities:
Proceeds from Mundipharma related to FOLOTYN collaboration (Note 16)	0	0	7,000
Proceeds from exercise of stock options	1,482	1,906	3,576
Proceeds from sale of stock under employee stock purchase plan	627	639	495
Purchase of treasury stock	0	0	(1,651)
Purchase and retirement of restricted stock to satisfy employee tax liability at vesting	(638)	(1,733)	(1,509)
Proceeds from revolving line of credit (Note 14)	0	0	100,000
Repayment of revolving line of credit (Note 14)	0	0	(175,000)
Proceeds from 2018 Convertible Notes (Note 15)	0	0	120,000
Deferred financing costs (Note 15)	0	0	(4,573)
Proceeds from sale of common stock warrants for 2018 Convertible Notes issuance (Note 15)	0	0	12,612
Purchase of common stock call options related to 2018 Convertible Notes issuance (Note 15)	0	0	(25,692)
Net cash provided by financing activities	1,471	812	35,258
Effect of exchange rates on cash and equivalents	(1,254)	(1,708)	(2,235)
Net (decrease) increase in cash and equivalents	9,799	(26,364)	16,608
Cash and equivalents — beginning of year	129,942	156,306	139,698
Cash and equivalents — end of year	139,741	129,942	156,306
Supplemental Disclosure of Cash Flow Information:
Cash paid for income taxes	335	329	0
Cash paid for interest	3,300	3,227	1,200
Retirement of treasury shares	0	0	1,652
EVOMELA [Member]
Cash Flows From Investing Activities:
Acquisition	0	0	(3,000)
Talon [Member]
Cash Flows From Investing Activities:
Acquisition	0	0	(11,169)
Supplemental Disclosure of Cash Flow Information:
Common stock issued for Talon acquisition	0	0	26,310
BELEODAQ [Member]
Cash Flows From Investing Activities:
Capitalized milestone payment upon FDA approval of BELEODAQ	$ 0	$ (25,000)	$ 0